Galenea

About:

Galenea is engaged in developing therapeutics for central nervous system diseases.

Website: http://www.galenea.com

Top Investors: National Institutes of Health

Description:

Galenea Corp., a biopharmaceutical company, engages in developing therapeutics for central nervous system (CNS) diseases. The company focuses on psychiatric disorders, schizophrenia and calcineurin, and obesity and 5-HT2C agonists. Its products include in vitro and in vivo synaptic functional screening and brain slice electrophysiology assays, which include techniques for recording disease-relevant neuronal activity in the prefrontal cortex to measure the effects of drug candidates in animals performing critical memory or cognition-dependent tasks. The company was founded in 2003 and is based in Cambridge, Massachusetts.

Total Funding Amount:

$13.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2004-01-01

Contact Email:

info(AT)Galenea.com

Founders:

David Gerber, Jianzhu Chen, Maria Karayiorgou, Susumu Tonegawa

Number of Employees:

51-100

Last Funding Date:

2012-09-06

IPO Status:

Private

Industries:

© 2025 bioDAO.ai